Dr. Reddy's Launches Aspirin And Extended-Release Dipyridamole Capsules In U.S.

A generic image of a line graph Credit: Shutterstock photo

(RTTNews.com) - Dr. Reddy's Laboratories Ltd (RDY) announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration.

The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules are available in 25 mg/200 mg strength with 60 count bottle size.

Read the original article on RTTNews (http://www.rttnews.com/2965151/dr-reddy-s-launches-aspirin-and-extended-release-dipyridamole-capsules-in-u-s.aspx)

For comments and feedback: contact editorial@rttnews.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.